Information  X 
Enter a valid email address

Creo Medical Group (CREO)

  Print      Mail a friend

Wednesday 24 April, 2019

Creo Medical Group

New video abstract featuring Speedboat published

RNS Number : 8282W
Creo Medical Group PLC
24 April 2019
 

Creo Medical Group plc

("Creo" or the "Company")

 

New video abstract featuring Speedboat published

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that the Company's Speedboat device has featured in a newly published video abstract entitled, "A new approach to endoscopic submucosal tunneling dissection: the "Speedboat-RS2" device".

 

The video abstract has been published via an open access content publisher, Thieme Group. It is available in the Endoscopy E-videos section and can be viewed online here:

 

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-0875-3352

 

The video abstract was authored by UK experts in the field of Gastrointestinal ("GI") therapeutic endoscopy and users of Creo's Speedboat device for colorectal endoscopic submucosal dissection, an advanced surgical procedure using endoscopy to remove gastrointestinal pre-cancerous lesions that have not entered the muscle layer.

 

The authors were:

-      Dr Zacharias Tsiamoulos, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

-      Dr Joseph Sebastian, Consultant Gastroenterologist at Queen Elizabeth the Queen Mother Hospital, East Kent

-      Dr Nipin Bagla, Consultant Histopathologist at Queen Elizabeth the Queen Mother Hospital, East Kent

-      Professor Brian Saunders, Consultant Gastroenterologist at St. Mark's Hospital Foundation

-      Dr Chris Hancock, Founder and Chief Technology Officer, Creo Medical Group plc

 

Craig Gulliford, Chief Executive Officer of Creo, commented:

"It is encouraging to see that additional case-studies of the effective clinical use of our Speedboat Device are being shared more and more widely amongst the Gastroenterological community. This video abstract provides another example of how our Speedboat technology provides precise dissection and controlled haemostasis using a single device. The technology will offer physicians a less invasive endoscopic surgical solution for removing pre-cancerous lesions in the colon, and one which significantly reduces procedure and recovery time as well as generating effective patient outcomes."

 

 

Creo Medical Group plc

 

Richard Rees (CFO)

+44 (0)129 160 6005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Mark Connelly (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Helen Cresswell

Mob: +44 (0)7841 917 679

 

 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRABDGDSSGDBGCX

a d v e r t i s e m e n t